AnnJi Pharmaceutical News

Dedicated to New Drug Development in Dermatology & Neurology

Dr. Wendy Huang, Chair and CEO of AnnJi Pharmaceutical Company Spoke on Consideration and Strategy of Candidates Selection in New Drug Development

On 9th, Dec. 2021, Clarivate held a webinar with the main theme “Patient demand is trending the candidate selection for new drug innovation and market entry strategies”, and invited Dr. Wendy Huang, Chair and CEO of AnnJi Pharmaceutical (AnnJi), as the keynote speaker to share her experiences.

Dr. Wendy Huang took the histone deacetylase 6 inhibitor (HDAC6i) program, which is under development by AnnJi for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) and idiopathic pulmonary fibrosis (IPF) as an example to illustrate how unmet medical needs and market potential, along with the druggability of the compound as key factors in the selection of new drug candidates.

For the full report, please refer to Global Bio & Investment.

To watch the webinar online, please refer to Clarivate.

Scroll to Top